Urology Times Registration and Sign Up Information | urologytimes

To view this email as a web page, click here.

MEN�S HEALTH MONDAY

Large study offers more evidence of ADT-Alzheimer�s link

""Of note, the number needed to treat analysis revealed that 18 patients treated with ADT resulted in one patient being diagnosed with Alzheimer�s and 10 patients treated with ADT resulted in one patient with a dementia diagnosis," writes Badar M. Mian, MD.

Read his column

ADT may increase likelihood of urethral atrophy

Androgen deprivation therapy for advanced prostate cancer may increase the likelihood of urethral atrophy in men with an artificial urinary sphincter (AUS), thereby contributing to an increased risk of AUS cuff erosion.

Learn more

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

Removing distal ureteral stones intact without laser fiber

Philip T. Zhao, MD, highlights the use of balloon dilation in a 61-year-old male with two stones at different locations within the right ureter. He discusses the steps, tools and guidelines to utilizing this efficient stone extraction technique to complete the case.

Watch the video now.

MORE FROM UROLOGY TIMES

Urethral lift found safe, efficacious in real-world setting

New nonmetastatic PCa agents address unmet need

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

BLADDER CANCER

Tecentriq plus chemotherapy extends PFS

Adding immunotherapy in the form of atezolizumab (Tecentriq) to platinum-based chemotherapy extends progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic urothelial carcinoma, according to results from a phase III study.

Read their column

Survival rates appear comparable for robotic, open cystectomy

�In treating a lethal disease such as muscle-invasive bladder cancer, our efforts must remain squarely focused on improving long-term disease control and survival,� writes Badar M. Mian, MD.

Read their column

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

Visit a Cysview� Reference Center in TX, OH, or CA

See hexaminolevulinate HCl in action in the operating room or clinic setting. Get answers and tips from an expert user. Travel and meal expenses are reimbursed. RSVP to discuss available dates and locations.

MORE FROM UROLOGY TIMES

How has FDA label change affected treatment of advanced bladder Ca?

DDR mutations linked to improved urothelial cancer outcomes

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

PROSTATE CANCER

PARP inhibitor significantly extends rPFS vs. hormonal therapy

The PARP inhibitor olaparib (Lynparza) significantly extended radiographic progression-free survival compared with physician�s choice of hormonal therapy in men with metastatic castration-resistant prostate cancer who had defects in genes involved in DNA repair mechanisms.

Get the data

Apalutamide efficacious in previously treated patients

Researchers say the use of apalutamide (Erleada) in patients with high-risk, nonmetastatic castration-resistant prostate cancer improves metastasis-free survival in patients who have previously undergone radical prostatectomy or external radiotherapy�regardless of the type of treatment they received.

Learn more

Video: Dr. Frydenberg discusses MRI�s potential as a screening tool

Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.

Watch the video

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

MORE FROM UROLOGY TIMES

New nonmetastatic PCa agents address unmet need

Fusion transcript shows potential for prostate cancer biomarker

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

PROSTATE CANCER

Sipuleucel-T significantly improves OS in African-Americans vs. Caucasians

Analyses of data collected in PROCEED, a large real-world registry, corroborate phase III study findings demonstrating that sipuleucel-T (Provenge) treatment for metastatic castrate-resistant prostate cancer has a particular benefit for improving overall survival in African-American men.

Learn more

Analysis further refines delivery of new therapies for mCRPC

"The last several years have been particularly exciting in the area of metastatic castrate-resistant prostate cancer," writes J. Brantley Thrasher, MD.

Read his editorial

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

MORE FROM UROLOGY TIMES

Antiandrogens may increase mortality risk in men with CVD

PSMA PET/CT beneficial for prostate cancer staging

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

CLINICAL UPDATES

Antiandrogens may increase mortality risk in men with CVD

Patients with CVD taking abiraterone or enzalutamide have a 43% higher risk of hospitalization, according to a recent study.

Read Dr. Badar Mian�s column

Prostate-sparing treatment uses nanoparticles

An ultrafocal photothermal ablation technique appears safe and feasible for low/intermediate-risk localized prostate cancer.

Learn more

Visit a Cysview� Reference Center in TX, OH, or CA

See hexaminolevulinate HCl in action in the operating room or clinic setting. Get answers and tips from an expert user. Travel and meal expenses are reimbursed. RSVP to discuss available dates and locations.

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

MORE FROM UROLOGY TIMES

Challenging case: Hematuria in man with a history of prostate Ca

Large study offers more evidence of ADT-Alzheimer�s link

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

BLADDER CANCER

Financial toxicity prevalent with bladder Ca patients

Financial toxicity is prevalent among patients with bladder cancer, according to findings from a cross-sectional study presented at the American College of Surgeons Clinical Congress in San Francisco.

Learn more

Tecentriq plus chemotherapy extends progression-free survival

�The results� support the use of atezolizumab in combination with chemotherapy as an important new treatment option for patients with untreated metastatic urothelial carcinoma,� says Enrique Grande, MD.

Get the data

MORE FROM UROLOGY TIMES

Survival rates appear comparable for robotic, open cystectomy

Pembro shows promising antitumor activity

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

MALPRACTICE CONSULT

Lack of follow-up on x-ray leads to lawsuit

"In this case, a key component to the defense verdict was the fact that the defendants were able to provide convincing expert testimony regarding the outcome of the decedent�s situation if the diagnosis had been tendered earlier, as argued by the plaintiff," writes Acacia Brush Perko, Esq.

Read her column

Not your patient? You can still be sued for malpractice

"It is prudent for providers to know the law of the jurisdiction where they practice and any applicable policies surrounding consult and documentation," advises Brianne Goodwin, JD, RN.

Learn more

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

MORE FROM UROLOGY TIMES

Resident, attending sued over BPH procedure

Who�s to blame for man�s loss of kidney function?

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

BLADDER CANCER

Cystoscopy overuse common in surveillance of low-risk bladder Ca

�The take home in my mind for the practicing urologist: For low-risk (low-grade) non-invasive urothelial carcinoma, less frequent surveillance cystoscopy is more,� says study author Florian R. Schroeck, MD, MS.

Learn more

Hematuria evaluation approaches compared

�The variability in recommendations [for hematuria evaluation] and our study�s findings highlight implicit value judgments and a potentially high burden of harms not historically considered in many guidelines� development process," says Matthew E. Nielsen, MD, MS.

Get the data

MORE FROM UROLOGY TIMES

Worse perioperative outcomes seen in bladder Ca patients ?80 years

Older women who quit smoking greatly reduce bladder cancer risk

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

PROSTATE CANCER

What do recent studies tell us about finasteride and PCa?

"The relevant professional associations in the field of medicine and/or urology must do their part to inform and educate their members about the appropriate use of finasteride and PSA to eliminate avoidable morbidity and mortality from prostate cancer," writes Badar M. Mian, MD.

Read his column

Challenging case: Hematuria in man with a history of prostate Ca

A 63-year-old African-American male presents to the emergency department with sudden onset of painless gross hematuria for one day. He reports dark red urine with clots causing occasional dysuria, difficulty emptying, and light-headedness.

Learn more

Salvage LND may help delay recurrence

A preliminary study of the use of salvage lymph node dissection in patients with nonmetastatic, castration-resistant prostate cancer indicates the potential to delay disease recurrence as well as the use of systemic therapies through this approach.

Get the data

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

MORE FROM UROLOGY TIMES

Prostate cancer in 9/11 responders: Study explores mechanism of action

Fat in abdomen, thigh linked to higher risk of aggressive prostate cancer

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

BLADDER CANCER

Bladder cancer biomarkers and BCG

Recent study findings have implications for noninvasive markers to predict the course of urothelial cell carcinoma.

Learn more

Untreated MIBC has short natural course, significant morbidity

"There appears to be a strikingly high likelihood of increased morbidity and poor outcomes in patient who are not receiving definitive therapy," writes Badar M. Mian, MD.

Read his column

MORE FROM UROLOGY TIMES

Metastatic bladder Ca: High ORR seen with immunotherapy combo

Gender disparities in bladder cancer management

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

BLADDER CANCER

Worse perioperative outcomes seen in bladder Ca patients ?80 years

A study investigating discharge destination and perioperative complications after radical cystectomy provides useful data for risk stratification and preoperative counseling of patients 80 years of age and older, said Hayden M. Hill, MD.

Get the data

Pyruvate kinase appears to be bladder cancer marker

Pyruvate kinase, a primary driver of tumor glycolysis, is promising both as a biomarker of bladder cancer and as a drug target, researchers report.

Learn more

Older women who quit smoking greatly reduce bladder cancer risk

Smoking�s strong impact on bladder cancer risk among men and women is clear, but a new study shows quitting smoking can greatly reduce risk of the cancer among menopausal women.

Dr. Hendryx discusses findings

Start 2020 with a Cysview� Reference Center Visit

See hexaminolevulinate HCl in action in the operating room or clinic setting. Get answers and tips from an expert user. Travel and meal expenses are reimbursed. RSVP to discuss available dates and locations

MORE FROM UROLOGY TIMES

Financial toxicity prevalent with bladder Ca patients

How has FDA label change affected treatment of advanced bladder Ca?

High-success approaches for bigger, more complex stones

Seth K. Bechis, MD, discusses a percutaneous approach to treating a 52-year-old patient with a large 4cm obstructed proximal ureteral stone. He highlights the steps and tools used in his technique, including effective lithotripter settings.

Watch the video now.

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

To view this email as a web page, click here.

Being the 'boss' of the graft

Our interview with Dr Lamis Baydoun on how corneal transplantation has changed-and what has been learned-since the introduction of Descemet membrane endothelial keratoplasty (DMEK)

COVID-19 implicated in conjunctivitis

The COVID-19 virus can cause ocular complications such as conjunctivitis, though not necessarily in the early stages of the disease, according to researchers

Visual impairment high among Rohingya refugees

Rohingya refugees are three- to six-times more likely to be blind than the native Bangladeshi population, but there are replicable, low-cost models for provide effective eye care in crisis settings.

Visual impairment high among Rohingya refugees

Rohingya refugees are three- to six-times more likely to be blind than the native Bangladeshi population, but there are replicable, low-cost models for provide effective eye care in crisis settings.

Pharmacologic treatment an option for open-angle glaucoma

There is no cure, but the disease can be managed with pharmacologic therapies, among other more invasive treatments, that lower and stabilize intraocular pressure (IOP).

Determining risk of ocular damage from chronic intravitreal injections

Because these injections have been used for a relatively short period, the definitive consequences of chronic use remain to be determined.

Learn more

Innovations from enucleation: Where can we go from here?

Ocular enucleation is inevitable for some patients; but for others, new therapies might spare the eye. If it must happen, there are ways to ease that road for patients.

Find out

Data Name	Data Type	Options
First name	Text Box
Last name	Text Box
Title	Text Box
Password	Text Box
Email	Text Box
Password (confirm)	Text Box

Start Searching Today!

Urology Times Sign Up Information

Email Address

Password

Your Name

Your Address

Post-Registration Data

Validation

Membership Emails

Comments about urologytimes

Recently added URLs

Top 10 Search URLs

Top 10 Categories